• AcelRx Pharmaceuticals Inc., of Redwood City, Calif., was issued U.S. Patent No. 8,226,978, "Small-Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment of Pain," and U.S. Patent No. 8,231,900, "Small-Volume Oral Transmucosal Dosage Forms." '978 deals with a dosage form for the oral transmucosal delivery of sufentanil, and '900 relates to a small-volume solid tablet that is a single dose of sufentanil for oral mucosal delivery.